GLYCOCONJUGATES AS CARRIERS FOR SPECIFIC DELIVERY OF THERAPEUTIC DRUGS AND GENES

被引:152
|
作者
MONSIGNY, M
ROCHE, AC
MIDOUX, P
MAYER, R
机构
[1] UNIV ORLEANS, BIOCHIM GLYCOCONJUGUES & LECTINES ENDOGENES LAB, F-45071 ORLEANS, FRANCE
[2] CNRS, CTR BIOPHYS MOLEC, F-45071 ORLEANS, FRANCE
关键词
ALLOPURINOL RIBOSIDE; AZT; CANCER CELLS; CHLOROQUINE; DRUG CARRIER; DRUG DELIVERY; ENDOCYTOSIS; FUSOGENIC PEPTIDES; GENE DELIVERY; GENE TARGETING; GLYCOSYLATED POLY-L-LYSINE; HIV; HSV; LEISHMANIA; MACROPHAGES; MEMBRANE LECTINS; NEOGLYCOPROTEINS; OLIGONUCLEOTIDES; PMEA; TRANSFECTION;
D O I
10.1016/0169-409X(94)90003-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cell surface receptors are good candidates to selectively target drugs, oligonucleotides or even genes by making use of their specific ligands. A large number of mammalian cells express cell surface sugar-binding proteins, also called ''membrane lectins''. Therefore, sugars may be used as specific recognition signals to specifically deliver biological active components. Tens of membrane lectins with different sugar specificities have been characterized; some of them actively carry their ligands to intracellular compartments, including endosomes, lysosomes and, in some cases, Golgi apparatus. In this review, we summarize the main properties of neoglycoproteins and glycosylated polymers; they have been developed to study the properties of endogenous lectins and to carry various drugs. Glycoconjugates have been successfully used to carry biological response modifiers such as N-acetylmuramyldipeptide. N-Acetylmuramyldipeptide is, in vitro, hundreds of times more efficient in rendering macrophages tumoricidal when it is bound to this type of carrier. In vivo, the N-acetylmuramyldipeptide bound to glycoconjugates containing mannose in a terminal nonreducing position, induces the eradication of lung metastases, occurring when treatment is started, in 70% of mice; free N-acetylmuramyldipeptide is strictly inactive. Similarly, N-acetylmuramyldipeptide bound to the same glycoconjugates induces an active antiviral effect. Glycoconjugates are also suitable for carrying antisense oligonucleotides specific for viral sequences. Antisense oligonucleotides protected at both ends and linked through a disulfide bridge to the glycoconjugates are 10 times more efficient than the corresponding free oligonucleotides. Poly-L-lysine containing about 190 lysine residues has been substituted by three components: sugars as recognition signal, antiviral (or antiparasite) agents as therapeutic elements and gluconoic acid as neutralizing and solubilizing agent. This type of neutral, highly water-soluble glycosylated polymer is a very efficient carrier to deliver drugs in infected cells according to the nature of the sugar borne on the polymer and to the specificity of the lectin present at the surface of the infected cells. Finally, poly-L-lysine (190 residues) partially substituted with sugars (60 units) is a polycationic glycosylated polymer which easily makes complexes with plasmids. These complexes are very efficient in transfecting cells in a surgar-dependent manner. The expression of reporter gene is greatly enhanced when cells are incubated with the plasmid-glycosylated poly-L-lysine complex in the presence of either 100 mu M chloroquine or 10 mu M fusogenic docosapeptide. Furthermore, this transfection method leads to a much larger number of stable transfectants than the classical method using calcium phosphate precipitate. The general properties of glycosylated proteins and of glycosylated polymers are presented and their efficiency in targeting genes in comparison with that of other available targeted transfection methods is discussed.
引用
收藏
页码:1 / 24
页数:24
相关论文
共 50 条
  • [1] Nanoscale carriers for targeted delivery of drugs and therapeutic biomolecules
    Kiparissides, Costas
    Kammona, Olga
    CANADIAN JOURNAL OF CHEMICAL ENGINEERING, 2013, 91 (04): : 638 - 651
  • [2] Cell-specific delivery of genes with glycosylated carriers
    Hashida, M
    Nishikawa, M
    Yamashita, F
    Takakura, Y
    ADVANCED DRUG DELIVERY REVIEWS, 2001, 52 (03) : 187 - 196
  • [3] Liposomes, new carriers for delivery of genes and anticancer drugs: a systematic review
    Salari, Nader
    Rasoulpoor, Shna
    Valipour, Elahe
    Mansouri, Kamran
    Bartina, Yalda
    Dokaneheifard, Sadat
    Mohammadi, Masoud
    Abam, Farzaneh
    ANTI-CANCER DRUGS, 2022, 33 (01) : E9 - E20
  • [4] DRUG TARGETING - APPLICATION OF ENDOGENOUS CARRIERS FOR SITE-SPECIFIC DELIVERY OF DRUGS
    VANBERKEL, TJC
    JOURNAL OF CONTROLLED RELEASE, 1993, 24 (1-3) : 145 - 155
  • [5] Nanocarriers for the Simultaneous Co-Delivery of Therapeutic Genes and Anticancer Drugs
    Choudhury, Nazia N.
    He, Huixin
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2012, 13 (07) : 1317 - 1331
  • [6] The Application of Chitosan and Its Derivatives as Nanosized Carriers for the Delivery of Chemical Drugs and Genes or Proteins
    Tang, Qilin
    Huang, Gangliang
    Ran, Rui
    Huang, Yanghua
    Lou, Qiaoping
    Chen, Yuzhu
    CURRENT DRUG TARGETS, 2016, 17 (07) : 811 - 816
  • [7] Drug Carriers for the Delivery of Therapeutic Peptides
    Du, Alice W.
    Stenzel, Martina H.
    BIOMACROMOLECULES, 2014, 15 (04) : 1097 - 1114
  • [8] Drug delivery carriers with therapeutic functions
    Cai, Shuting S.
    Li, Tianyu
    Akinade, Tolulope
    Zhu, Yuefei
    Leong, Kam W.
    ADVANCED DRUG DELIVERY REVIEWS, 2021, 176
  • [9] Dynamic carriers for therapeutic RNA delivery
    Berger, Simone
    Laechelt, Ulrich
    Wagner, Ernst
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2024, 121 (11)
  • [10] Design of liposomal carriers modified by glycoconjugates for liver cell delivery of nucleic acids
    Brazhnikov, G. T.
    Shilovskiy, I. P.
    Koloskova, O. O.
    Nosova, A. S.
    Sebyakin, Y. L.
    Khaitov, M. R.
    ALLERGY, 2018, 73 : 467 - 468